Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M09D1 in locally advanced or metastatic NSCLC and other solid tumors
NCT07056556Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BL-M09D1 in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
BL-M09D1
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT07056556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07056556.